In just 10 years after its discovery as a defence system against viruses in bacteria, CRISPR-Cas has taken the world by storm. The ability of CRISPR-Cas to target and change DNA sequences with unprecedented precision, has completely revolutionized the possibilities of genetic modification in science, medicine and (bio)technology. As such, this new technology has greatly impacted the precision, speed, ease, but also the costs by which genetic material can be altered. No matter whether it’s used to generate new genetically modified model organisms in the lab, curing (human) disease or generating new industrially-relevant production organisms: CRISPR-Cas appears to be the method of choice.

Introduction to CRISPR-Cas

Traditionally, Wageningen has fulfilled a pioneering role in discovering and characterizing new CRISPR-Cas systems and to rapidly adapt these for novel applications in science, industry and medicine, thereby showcasing the potential of how fundamental research can rapidly be translated to new, ground-breaking applications. During the Company Day you will discover what these applications can do for your organisation.

CRISPR-Cas Sessions

Each round, an introduction to CRISPR-Cas is given by assistant professor Raymond Staals (Laboratory of Microbiology, Wageningen University) on the wide range of present and future CRISPR-Cas based applications. Subsequently, you get the possibility to join two of the five sessions listed below.

Session 1: “Advances in genome editing using Cpf1 and application for industrial biotechnology”
Dr. Hans Roubos and Dr. René Verwaal; (Senior scientist genetics, DSM)

Session 2: “Development of a thermostable Cas9 for enhanced production of organic acids.
Prof. Richard van Kranenburg (Corporate scientist, Corbion and Special Professor Microbiology, WUR)

Session 3: “Case13a, a portable diagnostic device for RNA/DNA detection”
(iGEM2017 winning team Delft)

Session 4: "iTOP: CRISPR delivery with a pinch of salt”
Dr. Marco de Boer MBA, (CEO, NTrans Technologies)

Session 5: "Ethical dilemmas and the future of CRISPR-Cas technologies"
Wen Wu (PhD student, Bacterial Genetics, Laboratory of Microbiology, WUR)